In 2014, in a continuation of the NOAH study, with 114 HER2+ BC patients treated with NAC-cyclophosphamide/methotrexate/fluorouracil (CMF)+Trastuzumab, Prat et al. (2014) determined that patients with the HER2-enriched intrinsic subtype presented a comparatively higher ratio of pCR (Odds Ratio (OR) = 5.11, p < 0.009) [41]. Here, ERBB2 is linked to breast cancer.